



## BCR CEOs

Albert Bourla (Chair)

Hubertus von Baumbach

Christopher Boerner

Elçin Barker Ergun

Robert Davis

Joaquin Duato

Charl van Zyl

Richard Francis

Lars Fruergaard Jørgensen

Carlos Gallardo

Peter Guenter

Hervé Hoppenot

Paul Hudson

Daniel O'Day

Stefan Oelrich

Osamu Okuda

Dave Ricks

Hiroaki Ueno

Christopher Viehbacher

Christophe Weber

Pfizer

Boehringer-Ingelheim

BMS

Menarini

MSD

Johnson & Johnson

Lundbeck

TEVA

Novo Nordisk

Almirall

Merck Group

Incyte

Sanofi

Gilead

Bayer

Chugai

Eli Lilly

Mitsubishi Tanabe

Biogen

Takeda

## **Heads of Associations**

Thomas Cueni	IFPMA
David Reddy	IFPMA
Kenshi Kinoshita	JPMA
Nathalie Moll	EFPIA
Steve Ubl	PhRMA



**Albert Bourla**  
Chairman and Chief Executive  
Officer  
(Pfizer), President of IFPMA  
and Chair of the  
Biopharmaceutical Industry  
Roundtable (BCR)

As Chairman and Chief Executive Officer, Albert Bourla leads Pfizer in its purpose, “Breakthroughs that change patients’ lives,” with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health.

During his more than 30 years at Pfizer, Albert has built a diverse and successful career, holding several senior positions across a range of markets and disciplines. The global nature of his work— having lived and worked in nine different cities and led teams across five continents—has informed his understanding of the needs of patients and healthcare systems around the world and deepened his commitment to helping ensure equitable access to medicines and vaccines.

When he took the reins as CEO in January 2019, Albert accelerated Pfizer’s transformation to become a more science-driven, innovative company—divesting its non-science-based businesses and dramatically increasing its R&D and digital innovation budgets. To create a culture in which the company’s people and science could thrive, Albert and his leadership team established Pfizer’s Purpose Blueprint, which included four core values: courage, excellence, equity, and joy.

A powerful example of Pfizer’s capabilities and culture was seen in the company’s response to the COVID-19 pandemic. Refusing to accept public funding and instead investing more than \$2 billion dollars at-risk, Albert inspired colleagues to deliver a safe and effective vaccine in just eight months —a process that typically take 8-10 years—without compromising quality or integrity. A year later, continuing to move at the speed of science, Pfizer delivered the first FDA-authorized oral antiviral treatment for COVID-19 by implementing the same sense of urgency and new ways of working that had made the vaccine program so successful. The company is now applying many of these “lightspeed” principles to projects across a wide range of therapeutic areas, including cancer, cardiovascular disease, inflammatory conditions, and more. Albert wrote about the company’s experience developing a COVID-19 vaccine in his book, *Moonshot: Inside Pfizer's Nine-Month Race to Make the Impossible Possible*, which was a Bronze Medalist in the 2023 Axiom Awards and a Finalist for the National Jewish Book Awards. The book also appeared on the Wall Street Journal Bestseller list for four weeks and was selected by the Next Big Idea Book Club.

Under Albert’s leadership, Pfizer also has further strengthened its commitment to Environmental, Social and Governance (ESG) principles. This includes issuing the biopharmaceutical industry’s first Sustainability Bond addressing capital investments in both environmental and social initiatives; launching the company’s first ESG report; and completing an extensive priority issue assessment to confirm where and how Pfizer can have the greatest long-term impact.

Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. He has received honorary doctorates from the American College of Greece, the University of Patras, Touro University, The Technion-Israel Institute of Technology, and Aristotle University, as well as an honorary degree from Babson College.

In 2022, Albert received the Golden Cross Order of the Redeemer, conferred by the President of Greece; the Order of Boyacá, conferred by the President of Colombia; and the Order of the Independence from the First Degree, conferred by His Majesty King Abdullah II of Jordan. In the same year, he was named the 2022 Genesis Prize Laureate

in recognition of his leadership during the COVID-19 pandemic and received the Courage Against Hate Award from the Anti-Defamation League. He also received the 2022 Eisenhower Global Citizenship Award from the Business Council for International Understanding, the Distinguished Leadership Award, and the Peter G. Peterson Business Statesmanship Award from the Committee for Economic Development, the Gold Medal from Americas Society, the Bower Award in Business Leadership from The Franklin Institute, the Double Helix Award from Cold Spring Harbor Laboratory, the Humanitarian Award from the Simon Wiesenthal Center, and the Manufacturer of the Year from the National Association of Manufacturers' Leadership Council.

In 2021, he was named CEO of the Year by CNN Business, included in Insider Magazine's Most Transformative CEOs list and inducted into the Crain's New York Business 2021 Hall of Fame. That same year, he received the Appeal of Conscience Award in recognition of his extraordinary leadership in service of the global community and The Atlantic Council's Distinguished Business Leadership Award for his and Pfizer's work on the COVID-19 vaccine. He also was recognized with the Roy Vagelos Award from the Prix Galien Foundation, the Academy of Achievement Award in Science from AHEPA, the Golden Medal of Institution from Hellenic Open University, the David Rockefeller Award from the Museum of Modern Art, the Theodor Herzl Award from the World Jewish Congress, the Sparkle of Hope Award from Community Hope, and the Father of the Year Award from the National Father's Day Council. In 2020, he received the Meridian Global Leadership Award.

Albert is chairman of The Pfizer Foundation and Co-Chair of the Board of Directors for the Partnership for New York City. He is President of the International Federation of Pharmaceutical Manufacturers & Associations, a director on multiple boards—Pfizer Inc., and PhRMA—and a trustee of the United States Council for International Business. In addition, Albert is a member of the Council on Foreign Relations, the Business Roundtable, the Business Council, and the New York City Mayor's Corporate Council.



**Hubertus von Baumbach**  
Chairman of the Board of Managing Directors and Chief Executive Officer (Boehringer Ingelheim)

Hubertus von Baumbach has been Chairman of the Board of Managing Directors of Boehringer Ingelheim since July 2016.

Prior to being appointed Chairman of the Board, Mr. von Baumbach served as Chief Financial Officer since 2009 and previously held multiple leadership positions within Boehringer Ingelheim. He started his professional career in 1998 in the US affiliate of F. Hoffmann-La Roche AG in Nutley, New Jersey.

Mr. von Baumbach was trained as a bank clerk at Merck, Finck & Co. in Munich, received his law degree from the Ludwig-Maximilians-Universität in Munich, took the German Bar Exam, and received a MBA from Sloan School of Management at Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts.

Mr. von Baumbach serves as a Member on Boards and Advisory Boards of both national and international industry associations as well as not-for-profit organizations.



**Christopher Boerner**  
Board Member and Chief Executive Officer  
(Bristol-Myers Squibb)

Dr. Christopher Boerner, age 52, serves as chief executive officer for Bristol Myers Squibb since November 2023. Prior to assuming that role, he was executive vice president, chief operating officer and chief executive officer designate since April 2023. Previously, he served as executive vice president, chief commercialization officer from August 2018 to April 2023. Dr. Boerner served as head of International Markets at Bristol Myers Squibb from September 2017 to July 2018, and as president and head of U.S. Commercial Markets from February 2015 to September 2017.

From 2010 to 2015, Dr. Boerner held leadership roles of increasing responsibility at Seattle Genetics, Inc. From 2002 to 2010, he served in marketing leadership roles at Genentech, a member of the Roche Group, focused on strategy, development and commercialization across multiple oncology products and immunology. Earlier in his career, he worked for McKinsey & Company, serving global pharmaceutical and biotechnology clients.

Dr. Boerner is a member of the Executive Committee of BIO (Biotechnology Innovation Organization) and a member of the National Council for Arts and Sciences at Washington University.



**Elçin Barker Ergun**  
Group CEO  
(Menarini)

Elcin Barker Ergun worked in Global, Regional and Local Leadership roles in Pharma Industry for more than 20 years in Innovation, Commercial and Finance Leadership.

She joined Menarini Group in September 2019 as Group CEO and Member of the Board of Directors after an expansive International career in the US, Europe and Emerging Markets.

Elcin entered Pharma Industry with Glaxo Smithkline as subsidiary CFO. She then joined Serono as General Manager, and took roles of increasing seniority over the years in Merck Serono as Senior Vice President, Regional Head of MEA, Russia, CIS and as Executive Vice President, Chief Commercial Officer when she was based in the group's headquarters in Germany. In her last role at Merck, she was based in Boston for 3 years as Executive Vice President, Head of New Businesses leading the external innovation led growth of new businesses.

In her earlier career, Elcin worked in the UK for Honeywell and in the Netherlands for ITT Corporation in IT Management where she started as a software engineer.

Elcin has a BSc degree in Computer Engineering from METU and an MBA from INSEAD.







**Robert M. Davis**  
Chief Executive Officer and



Rob Davis is Chief Executive Officer and President of Merck.

Previously, Rob served as Merck's President, responsible for the company's operating divisions — Human Health, Animal Health, Manufacturing and Merck Research Laboratories. Prior to that, he was executive vice president, Global Services, and the company's chief financial officer.

Rob joined the company as Chief Financial Officer in 2014 with additional responsibility for real estate operations, corporate strategy and business development. In 2016, his role was expanded to include responsibility for information technology and procurement, forming Global Services. He became President in April 2021 and CEO and a member of the board of directors on July 1, 2021.

<p>President (MSD)</p>	<p>Prior to joining Merck, Rob was Corporate Vice President and President of Baxter’s Medical Products business. During his tenure at Baxter, he held several other positions, including president of Baxter’s Renal business, Chief Financial Officer and treasurer. Before joining Baxter in 2004, Rob held numerous positions of increasing responsibility over 14 years at Eli Lilly and Company.</p> <p>Rob serves on the Board of Directors for Duke Energy Corporation and is Chair of its finance and risk management committee and a member of the corporate governance committee. In addition, Rob is a Board Member of Project Hope, a non-profit organization focused on empowering health care workers to deliver expert care when and where it is needed most.</p> <p>Rob received his J.D. from Northwestern University School of Law, his M.B.A. from Northwestern University’s Kellogg Graduate School of Management and his bachelor’s degree in finance from Miami University.</p>
 <p><b>Joaquin Duato</b> Chairman and Chief Executive Officer (Johnson &amp; Johnson)</p>	<p>Joaquin Duato is Chairman of the Board and Chief Executive Officer of Johnson &amp; Johnson, the world’s largest, most diversified healthcare products company. He leads a global workforce in developing and delivering transformational and innovative healthcare solutions in Pharmaceuticals, MedTech, and Consumer Health.</p> <p>Joaquin believes in the power of technology to accelerate progress in healthcare. Under his leadership, scientific expertise combined with AI and machine learning is accelerating how Johnson &amp; Johnson confronts the most complex healthcare challenges and delivers for patients.</p> <p>A dual citizen of Spain and the United States, Joaquin believes that his international perspective has deepened his appreciation of diversity in all forms. He is committed to building an inclusive workforce that reflects the patients Johnson &amp; Johnson serves.</p> <p>Joaquin earned an MBA from ESADE in Barcelona, Spain, and a Master of International Management degree from Arizona State University’s Thunderbird School of Global Management. Joaquin lives in Pennsylvania with his wife and has two grown children. He enjoys spending time with his family, and is an avid soccer and tennis fan.</p>
 <p><b>Richard Francis</b> President and Chief Executive Officer (TEVA)</p>	<p>With over two and a half decades of leadership positions in various pharmaceutical companies and a proven track record in the pharmaceutical, biotech and generics sectors, Mr. Francis provides an entrepreneurial, pragmatic and unique global perspective on the healthcare and pharmaceutical industries.</p> <p>Mr. Francis became Teva’s President and Chief Executive Officer and a member of the Board of Directors on January 1, 2023. Prior to joining Teva, Mr. Francis served as the Chief Executive Officer of Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, from 2021 to 2022, and as the Chief Executive Officer of Forcefield Therapeutics, a pioneer of best-in-class therapeutics to protect heart function, from 2021 to 2022. He also served as an operating partner for Syncona Investment Management Limited since 2021.</p>

	<p>From 2014 to 2019, Mr. Francis served as Chief Executive Officer of Sandoz and a member of the executive team of Novartis. Prior to his role at Sandoz, Mr. Francis was a senior executive at Biogen for 13 years, where he held a number of senior roles, including leading Biogen's U.S. business. Mr. Francis also serves as a member of the board of directors of Mettler-Toledo International Inc. since 2016. He holds a Bachelor of Arts in Economics from The Manchester Metropolitan University.</p>
 <p><b>Lars Fruergaard Jørgensen</b> President and Chief Executive Officer (Novo Nordisk)</p>	<p>Lars joined Novo Nordisk in 1991 as a business graduate in Health Care, Economy &amp; Planning where he rotated over three years between functions in Finance, Production and Marketing in Denmark and the Netherlands.</p> <p>From 1994 to 2001, his responsibilities gradually increased when he was appointed head of finance functions in the Danish affiliate of Novo Nordisk and later in the company's production facilities in Clayton, North Carolina, US. In 2001, he became vice president for Finance &amp; IT in Japan and moved with his family to Tokyo. He moved back to Denmark in 2004 when he was appointed senior vice president for Novo Nordisk's IT &amp; Corporate Development.</p> <p>January 2013, he was appointed executive vice president and chief information officer assuming responsibility for IT, Quality &amp; Corporate Development. November 2014, he took over the responsibilities for Corporate People &amp; Organisation and Business Assurance and became chief of staff. From 1 January 2017, he has been president and chief executive officer of Novo Nordisk A/S.</p> <p>Since 1 January 2021, Mr Fruergaard Jørgensen has served as vice president of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and as of 21 June 2023 he will be president of EFPIA.</p>
 <p><b>Carlos Gallardo</b> Chairman and Proprietary Director</p>	<p>Carlos joined the pharmaceutical industry 20 years ago when he joined Pfizer based in New York, upon graduating from Stanford Graduate School of Business.</p> <p>In 2004, he joined Almirall where he has remained until the present day. First as an executive in different countries and positions ranging from Strategy, Sales, Licensing, M&amp;A and to Country Management. In 2013, he was appointed Board Director. He became Vice Chairman in 2020 and Chairman in May 2022. In November 2022, he was appointed interim CEO and as from February 2023 the permanent position as CEO.</p> <p>Additionally, Carlos has established a successful career in innovative healthcare technology. He is the founder and CEO of CG Health Ventures, which invests in early-stage digital health and medtech companies globally, providing a unique blend of operational support and capital. Carlos serves on a number of boards of promising</p>

<p>(Almirall)</p>	<p>early-stage companies.</p> <p>Before joining the pharmaceutical industry, Carlos worked as an engineer in the automotive industry in logistic supply chain. He holds a MS in industrial engineering from the Universitat Politècnica de Catalunya.</p>
 <p><b>Peter Guenter</b> Member of the Executive Board (CEO Healthcare)</p>	<p>Peter Guenter is a member of the Executive Board and CEO of Healthcare at Merck. When he started in January 2021, he set a clear strategy with the ambition to outperform the pharmaceutical market. He is aiming for leadership where the business is strong and focusing on key innovations to address high unmet medical needs. Under his leadership more than 17,500 employees are driven by a common purpose to help create, improve, and prolong lives – as one for patients.</p> <p>Before joining Merck, Peter served as CEO of the biopharmaceutical company Almirall, based in Barcelona, Spain, from 2017 to 2020. In this time, he led a strategic and cultural transformation to build a global skin-health focused company and brought the business back on track for growth. Prior to this, Peter worked at Sanofi for 22 years where he was a member of the Executive Committee since 2013. During his tenure there, Peter held a range of local, regional, and global leadership roles and was among other things responsible for Global Commercial Operations.</p> <p>Peter is a Member of the Board of the European Federation of Pharmaceutical Industries and Associations (EFPIA) where he also took over as the Chair of the Innovation Board Sponsored Committee (BSC) in January 2023. Peter Guenter was born in 1962 in Ghent, Belgium. He holds a Master’s degree in Physical Education from the Faculty of Medicine and Health Sciences of the University of Ghent.</p>
 <p><b>Hervé Hoppenot</b> Chief Executive Officer (Inyte)</p>	<p>Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer and was appointed Chairman of the Board of Directors in 2015.</p> <p>During Mr. Hoppenot’s tenure, the company has tripled the number of clinical candidates in its portfolio, expanding beyond Oncology to include research and development in Inflammation &amp; Autoimmunity. Under his leadership, revenue has increased by nearly 600%, which includes the addition of five new sources of potential revenue. With a goal to deliver medicines to patients worldwide, Incyte has expanded geographically and has operations in North America, Europe and Asia.</p> <p>Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology. He began his career at Novartis in 2003 as Chief Commercial Officer and later became President in 2010. Mr. Hoppenot started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School.</p>





**Paul Hudson**  
Chief Executive Officer (Sanofi)

Paul Hudson is leading the execution of Sanofi's strategy, a five-year plan (2020-2025) designed with the ambition to leverage breakthrough science to change the practice of medicine and to foster a workplace where people can bring their best selves to work.

The strategy has sharpened the focus on key R&D areas, including immunology, vaccines, hemophilia, oncology, and rare diseases, with the objective of delivering breakthrough solutions to patients and improve people's health worldwide. Under Paul's leadership, and in the middle of a global pandemic, Sanofi has renewed its commitments to society, putting sustainability and social responsibility at the core of its long-term strategy.

Before joining Sanofi, Paul was CEO of Novartis Pharmaceuticals from 2016 to 2019, and a member of the Novartis Executive Committee. His career in healthcare has spanned the globe, with assignments in the US, Japan and Europe. Prior to Novartis, he worked for AstraZeneca, where he held several increasingly senior positions and most recently carried out the roles of president, AstraZeneca US and executive vice president, North America. He began his career in sales and marketing roles at GlaxoSmithKline UK and Sanofi-Synthélabo UK.

Paul holds a degree in economics from Manchester Metropolitan University in the UK, and in July 2018 his alma mater awarded him an honorary Doctor of Business Administration for his achievements in industry.



**Daniel O'Day**  
Chairman and Chief Executive Officer  
(Gilead)

Daniel O'Day joined Gilead Sciences in March 2019 as Chairman of the Board of Directors and Chief Executive Officer.

Prior to Gilead, Daniel served as the Chief Executive Officer of Roche Pharmaceuticals. His career at Roche spanned more than three decades, during which he held a number of executive positions in the company's pharmaceutical and diagnostics divisions in North America, Europe and Asia.

He served as a member of Roche's Corporate Executive Committee, as well as on a number of public and private boards, including Genentech, Flatiron Health and Foundation Medicine.

Daniel O'Day holds a bachelor's degree in biology from Georgetown University and an MBA from Columbia University in New York. He currently serves on the board of directors for the Pharmaceutical Research and Manufacturers of America organization and Galapagos NV.



**Stefan Oelrich**  
Chief Executive Officer,  
Pharmaceuticals

Stefan Oelrich is a member of the Board of Management of Bayer AG and President of its Pharmaceuticals Division, a position he has held since November 2018.

Prior to joining the company, he was on the Executive Committee of Sanofi, leading its global Diabetes & Cardiovascular business. During his seven-year tenure, he was also at the helm of Sanofi Germany, Switzerland and Austria, as well as the Diabetes and Cardiovascular business unit in Europe.

From 1989 to 2011, Mr. Oelrich held various leadership positions in the health care business of Bayer AG with extensive international experience spanning Latin America (Argentina, Uruguay), Europe (France, Belgium) and the United States.

Mr. Oelrich is a member of the Supervisory Board of the university hospital Charité.

(Bayer)



**Osamu Okuda**  
Representative Director,  
President and Chief Executive  
Officer  
(Chugai Pharmaceutical)

Currently serving as Representative Director, President & CEO of Chugai Pharmaceutical Co., Ltd., Dr. Osamu Okuda was named Chief Operating Officer in 2020 before assuming the role of Chief Executive Officer in 2021.

Born in Gifu, Japan in 1963, Dr. Okuda graduated from Gifu Pharmaceutical University of Pharmaceutical Science before joining Chugai in 1987. He received his Ph.D. in Pharmaceutical Science at Osaka University in 1995.

He served as Lifecycle Leader for Actemra (2009-2011) before becoming a Managing Director of Roche Products (Ireland) Ltd. in 2011. He then served as Vice President & General Manager of Chugai, led Oncology, Marketing and Sales, Corporate Planning, and Project-Lifecycle Management before becoming Representative Director.



**Dave Ricks**  
Chair and Chief Executive  
Officer  
(Eli Lilly and Company)




Dave Ricks is Chair and Chief Executive Officer of Eli Lilly and Company. A Lilly veteran for more than 25 years, with experience in marketing, sales, drug development and international operations, Dave became CEO in January 2017 and was elected chair of the company's board of directors effective June 2017.


Dave served as president of Lilly Bio-Medicines from 2012 through 2016. He led the company's largest affiliate, Lilly USA, as president from 2009 to 2012.

Prior to that, Dave served in international leadership roles for nearly eight years. He served as president and general manager of Lilly China, operating in one of the world's fastest-growing emerging markets, from 2008 to 2009. He led Lilly Canada as general manager from 2005 to 2008, after roles as director of pharmaceutical marketing and national sales director in that country. Dave joined Lilly in 1996 as a business development associate and held several management roles in U.S. marketing and sales before moving to Lilly Canada.

Dave earned a Bachelor of Science degree from Purdue University in 1990 and a Master of Business Administration degree from Indiana University in 1996.

Dave serves on the board of directors for Adobe and Business Roundtable. In addition, he is a member of the board and former board chair of Pharmaceutical Research and Manufacturers of America. Dave is a member of the International Federation of Pharmaceutical Manufacturers & Association's CEO Steering Committee, The Business Council and the U.S. Patent and Trademark Office's Council for Inclusive Innovation.

	<p>Closer to home, Dave is heavily engaged in the development and well-being of Central Indiana and serves on the executive committee and board of Central Indiana Corporate Partnership</p>
 <p><b>Hiroaki Ueno</b> Representative Director (Mitsubishi Tanabe)</p>	<p>Hiroaki Ueno was born in Aichi, Japan, in 1958. He received a Ph.D. in Chemistry at the Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology. He joined with pharmaceutical division of Mitsubishi Chemical Industries in 1983, which was merged with Tanabe Seiyaku in 2007 to be Mitsubishi Tanabe Pharma corporation. He spent his career for drug discovery research and development in past.</p> <p>He was promoted to be an executive officer in 2014-2017, a managing executive officer in 2018-2019, and a member of the board in 2019. From 2020 to present, he is a representative director of Mitsubishi Tanabe and a vice president of JMPA.</p>
 <p><b>Charl van Zyl</b> President and Chief Executive Officer (Lundbeck)</p>	<p>Charl van Zyl joined Lundbeck as President &amp; CEO in September 2023. He brings more than 23 years of experience from commercial international management roles within the pharmaceutical industry, most recently in the field of immunology and neurology from UCB where he served as Executive Vice President (EVP) and Head of Neurology globally, responsible for corporate activities in Europe and international markets.</p> <p>Besides UCB where he previously also held a position as Chief Operating Officer, his career includes positions such as EVP at BSN Medical, Corporate VP &amp; Commercial Leader EMEA at Bausch &amp; Lomb, CEO at JADO Technologies, Head of Marketing and Sales at Novartis Pharma and Business Unit Manager at Eli Lilly and Company.</p> <p>Charl is South African and holds a degree in Medical Biochemistry from the University of Cape Town, South Africa. He has lived and worked in South Africa, United States, Japan, Switzerland, Belgium and now Denmark.</p>
 <p><b>Christopher Viehbacher</b> President and Chief Executive Officer</p>	<p>Christopher A. Viehbacher joined Biogen as President and Chief Executive Officer and a member of the Board of Directors in November 2022. Viehbacher has extensive international experience in both large pharmaceutical companies and entrepreneurial biotech companies and has a passion for advancing science for the benefit of patients and public health.</p> <p>After 20 years with GlaxoSmithKline, he served as global CEO of Sanofi for six years. Under Viehbacher's leadership, Sanofi strengthened and diversified its R&amp;D pipeline and delivered significant value to shareholders.</p> <p>More recently, Viehbacher and Ernesto Bertarelli co-founded Gurnet Point Capital, a Cambridge-based healthcare investment fund, which has led to the creation and continuing development of many innovative companies. He has also chaired or been a member of the board of a number of entrepreneurial companies in biotechnology.</p>

<p>(Biogen)</p>	<p>Viehbacher has always been a strong advocate for innovation and public health. He has received a number of awards including the Légion d'Honneur from France.</p> <p>He graduated from Queen's University in Kingston, Ontario, Canada. He is a certified public accountant, and he speaks French, German and English.</p>
 <p><b>Christophe Weber</b> Chief Executive Officer (Takeda)</p>	<p>Christophe Weber is President, Chief Executive Officer (CEO) and Representative Director of Takeda Pharmaceutical Company Ltd. He joined the company in April 2014 as Chief Operating Officer, was named President and Representative Director in June 2014, and was subsequently appointed CEO in April 2015. Mr. Weber has focused on Takeda's R&amp;D transformation and globalization, creating a diverse and inclusive working environment while strengthening its ethical values and corporate governance. Through this transformation, Takeda became one of the leading global biopharmaceutical companies in the world.</p> <p>Prior to joining Takeda, Mr. Weber spent 20 years at GlaxoSmithKline (GSK), where he held senior leadership roles in Europe, Asia and the United States.</p> <p>Outside of Takeda, Mr. Weber is member of The Business Council, the World Economic Forum's International Business Council, the Singapore Economic Development Board's International Advisory Council, the New York Stock Exchange's NYSE Board Advisory Council and the MIT CEO Advisory Board. He also serves on the Board of Trustees of Northeastern University.</p> <p>Mr. Weber holds a doctorate in pharmacy and pharmacokinetics, master's degrees in pharmaceutical marketing and in accounting and finance and a degree in statistics, from the University of Lyon, France.</p>



**Thomas B. Cueni**

Director General,  
International Federation of  
Pharmaceutical Manufacturers and  
Associations (IFPMA)

Secretary,  
Biopharmaceutical CEO Roundtable  
(BCR)

Thomas Cueni has led IFPMA since 2017, during which time he has been instrumental in establishing cross sectoral programs designed to tackle the biggest global health challenges.

This includes establishing the \$1bn AMR Action Fund to support the development of new antibiotics; as Chair of the AMR Industry Alliance; as a member of the Board of City Cancer Challenge; as Chair of the Business at OECD Health Committee and as the industry's representative on the Access to COVID-19 Tools (ACT) Accelerator.

Leading the IFPMA through the COVID-19 pandemic, Thomas galvanised the industry to develop the Berlin Declaration – the pharmaceutical industry's blueprint to deliver equitable access to vaccines, treatments, and diagnostics in future pandemics. Thomas serves as Industry Co-Chair of the APEC Biopharmaceutical Working Group on Ethics. He is also a member of the Business Advisory Group established by the Director General of the World Trade Organization.

Prior to joining IFPMA, Thomas was Secretary General of Interpharma, the trade association representing Switzerland's research-based pharmaceutical industry; Secretary of the Dolder Group, precursor of what's now the BCR; and served on the Board of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Thomas began his career as a journalist, as London correspondent for the Basler Zeitung and Der Bund, before serving as a Swiss diplomat in Paris (OECD) and Vienna (IAEA, UNIDO).

Thomas has a master's degree in economics from the University of Basel and another in politics from the London School of Economics. He also studied at the Geneva Graduate Institute for International Studies.



**David Reddy**

Incoming Director General,  
International Federation of  
Pharmaceutical Manufacturers and  
Associations (IFPMA)

Secretary,  
Biopharmaceutical CEO Roundtable  
(BCR)

David Reddy succeeds Thomas Cueni as IFPMA Director General from April 2024.

David's background is as a scientist. He has more than 30 years' experience in the development and commercialization of medicines, including 13 years as the head of the Medicines for Malaria Venture (MMV). In his role at MMV and in industry prior to that, David accumulated significant experience interfacing with governments, international organizations, NGOs, and patient advocacy groups around access to medicines for priority diseases, including HIV/AIDS and pandemic influenza.



**Kenshi Kinoshita**  
Director General  
(JPMA)

After graduating from Hitotsubashi University, Faculty of Economics in 1983, Mr. Kinoshita joined Ministry of Health and Welfare (MHLW).  
From 2009-2019, he was assigned to Director, General Affairs Division, Health Insurance Bureau, MHLW, Deputy Director-General, Minister's Secretariat, Cabinet Office, Deputy Director-General, Minister's Secretariat, MHLW, Deputy Director-General, Cabinet Secretariat, and Director-General, Pension Bureau, MHLW.  
From 2019-2020, he was assigned to Director-General, Cabinet Secretariat.  
From 2021 to 2023 was appointed as Advisor, Public Corporations Department, Mizuho Bank, Ltd.  
From 2023- serves as a Director General of Japan Pharmaceuticals Manufacture Association.



**Nathalie Moll**  
Director General,  
European Federation of  
Pharmaceutical Industries and  
Associations (EFPIA)

Nathalie Moll joined the European Federation of Pharmaceutical Industries and Associations (EFPIA) as Director General in April 2017.

EFPIA represents the pharmaceutical industry operating in Europe. Together with its direct membership 40 leading pharmaceutical companies, 33 national associations representing over 1,900 companies and in collaboration with health and research players, EFPIA's mission is to create an environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.

Prior to joining EFPIA, between 2010 and 2017 Nathalie was the Secretary General of EuropaBio ranked as the most effective European Trade Association in Brussels in 2013. She spent over 20 years working for the biotech industry at EU and national level in associations and corporate positions and held the position of Chair and Vice Chair of the International Council of Biotech Associations (ICBA).

In 2013, Nathalie won the Technovisionaries Women Innovation Award organised by Women & Technologies® while in 2009, Nathalie and the Green Biotech Team of EuropaBio were presented with the Leadership and Excellence in Advancing Ag-Biotech and Food Issues Award. Nathalie was also named one of the 15 leading women in biotech in Europe in 2017 and recognised as one of the "20 Women Who Shape Brussels" by POLITICO Europe in 2020.

Nathalie holds an Honours Degree in Biochemistry and Biotechnology from St Andrews University, Scotland.



**Stephen J. Ubl**

President and Chief Executive Officer  
Pharmaceutical Research and  
Manufacturers of America (PhRMA)

Stephen J. Ubl is president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America's leading biopharmaceutical research companies. The U.S. biopharmaceutical sector directly employs more than 800,000 Americans and invests more than \$100 billion in research and development annually -- more than any other industry in America.

Mr. Ubl leads PhRMA's work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. Ubl is recognized around the world as a leading health care advocate and policy expert who collaborates successfully with diverse stakeholder groups -- including patient and physician groups, regulators, public and private payers, and global trade organizations -- to help ensure timely patient access to innovative treatments and cures. "If anyone can find areas of agreement with the critics, or at least work productively with them, it may be Mr. Ubl," the New York Times wrote in February 2016. "He is more conversant with the intricacies of health policy, and more adept at the politics."

As president and CEO of medical technology association AdvaMed, Ubl helped facilitate landmark reforms related to the U.S. Food and Drug Administration product review process and Medicare's coverage and reimbursement of medical technologies. He led the industry's defense of breakthrough R&D, successfully delaying an innovation-stifling device tax, and, in 2013, was recognized by a leading industry publication as one of 10 people to have a lasting impact on the medical technology industry.

Ubl has worked extensively with patient advocacy organizations in health policy, including longstanding service on the board of the National Health Council, a leading umbrella organization for voluntary health care organizations and has been personally involved with JDRC (formerly known as the Juvenile Diabetes Research Foundation).

He is routinely recognized as one of Washington's most effective advocates, and, in 2019, was named one of Business Insider's "DC Healthcare Power Players." He is consistently named to Modern Healthcare's "100 Most Influential People in Healthcare" list and is identified as a top health influencer by Medical Marketing & Media and PR Week magazines. Prior to AdvaMed, Ubl was Vice President of legislation for the Federation of American Hospitals. He began his Washington career on Capitol Hill.